Interestingly, the administration of one such neuropeptide, i.e., Neuropeptide S (NPS) into the APP/PSI mouse model of Alzheimer’s disease (AD), has been shown to result in the reduction of β-Amyloid plaques indicating the clinical relevance of employing neuropeptides in treating age related disorders of the brain (Zhao et al., 2019). Here, PPIB is linked to Alzheimer disease.